Ro Research Lab: the telehealth firm turning millions of patient journeys into AI medical discovery

Ro knows the question that matters most about a weight-loss drug: why does one patient lose 35% of their body weight on it while another loses 5%? The telehealth firm launched Ro Research Lab on November 6, 2026, an initiative that pairs AI with real-world data from millions of patient journeys to turn everyday care into medical evidence.

The lab’s pitch is that medicine’s bottleneck is not a lack of data, but a lack of connected data. “Medicine is incredible. It saves lives. But it takes too long to go from insight to intervention, and then to scale,” Ro said in its launch announcement. The lab will use AI to find patterns in patient data and rigorous science to prove them, working with clinicians and academic researchers.

The question at the heart of it

The launch announcement frames the lab around the outliers: why do some people lose 35% of their body weight on a medication while others lose 5%? Why do some experience significant side effects while others have none? How do genetics, behaviours and treatment decisions shape outcomes? “These are the outliers — and as history has shown, the outliers are often where breakthroughs hide,” Ro said.

“Imagine being able to identify the faintest footsteps of a disease, understand exactly which intervention will work for someone, and deliver it at the right moment,” said Zach Reitano, Ro’s co-founder and CEO. “Help one person achieve their health goals, and you unlock their full potential. Do that at scale, and you unlock the full potential of humanity.”

A data stream most labs don’t have

Ro’s advantage is that patient care on its platform already generates a continuous stream of data: side effects, lab results, changes in sleep and heart rate, and numbers on the scale. By bringing clinical care, pharmacy, labs and patient-reported outcomes together on one platform, Ro says it can connect those insights across millions of patient journeys.

The company has served patients since 2017 in nearly every county in the United States, including 99% of primary care deserts, and says it is the only company offering nationwide telehealth, labs and pharmacy services. That reach is the point: the lab’s dataset is not a trial cohort, it is people receiving ordinary care.

Already publishing

The lab had begun publishing before its formal launch. Its publications catalogue already lists an evaluation of an AI triage tool for GLP-1 care: a custom language model that detected patient messages about current or recent adverse events, classified their severity and flagged high-priority cases for licensed care-team review. The study reported a 94% true-positive rate, and the median time to first clinical response fell from 115.1 minutes to 33.0 minutes. An exercise analysis and a GLP-1 Pipeline Tracker, which follows press releases, published papers and ClinicalTrials.gov records, are both dated October 29, 2026.

Ro says early findings will be labelled as such, and what holds up will go through peer review. The topics it plans to share findings on range from heart attacks, sex, food noise and mental health to what’s in your grocery cart. “Some discoveries might make you text your doctor. Others, your group chat,” the company said.

The drugmaker angle

The lab is also a business move. Reuters reported that Ro is in talks with drug manufacturers about partnering with its research unit, and that the company entered a research collaboration with drugmaker Amgen this year to study access to obesity treatments. More data could help insurers weighing coverage of expensive medications, help drugmakers identify which patients benefit from a specific treatment, and improve outcomes for people on the platform, Reitano told Reuters.

Ro offers cash-pay access to Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy through the manufacturers’ direct pharmacies, although eligible patients can use insurance. As some employers drop coverage of the drugs over rising costs, Reitano said stronger real-world evidence could help insurers see the longer-term health and cost benefits of covering them.

A crowded field, a different dataset

Ro is not the only AI lab chasing health data. Kyunghyun Cho’s Ortet is a $500M frontier AI lab building a patient-centered health model, Atlas Bio emerged from stealth with $12.5M to replace Phase II trials with AI virtual patients, and OpenAI acquired Orchestra Bio to put AI agents on drug-development grunt work. Ro’s bet is different: not simulated patients or a new model, but real patients, real outcomes, and a dataset that grows every time someone gets care. Whether that turns into peer-reviewed breakthroughs — or just a better sales pitch to drugmakers — is what the lab now has to prove.